Risk Factors of Subsequent Primary Melanomas in Austria.


Journal

JAMA dermatology
ISSN: 2168-6084
Titre abrégé: JAMA Dermatol
Pays: United States
ID NLM: 101589530

Informations de publication

Date de publication:
01 02 2019
Historique:
pubmed: 20 12 2018
medline: 18 10 2019
entrez: 20 12 2018
Statut: ppublish

Résumé

Information on risk factors of subsequent melanomas would be helpful to identify patients at risk after the diagnosis of their first melanomas. To determine risk factors of subsequent melanomas. In this retrospective case-control study, 1648 participants with histologically verified cutaneous melanoma diagnosed from January 1, 1968, though March 16, 2015, were recruited from a tertiary referral center as part of the Molecular Markers of Melanoma study. CDKN2A was sequenced in 514 and MC1R in 953 participants. Data were analyzed from March 7, 2008, through March 25, 2015. Phenotypic traits and internal and external risk factors for the development of a second, third, or fourth melanoma. In total, 1648 patients (53.6% men; mean [SD] age, 54 [15] years) were enrolled, including 1349 with single and 299 with multiple primary melanoma. Mean (SD) age at recruitment was 57 (15) years for the single-melanoma and 62 (14) years for the multiple-melanoma groups. From the internal risk factors, family history (odds ratio [OR], 1.76; 95% CI, 1.22-2.55; P = .006), CDKN2A high-risk mutations (OR, 4.03; 95% CI, 1.28-12.70; P = .02), and high numbers of nevi as a phenotypic risk factor (ORs, 2.23 [95% CI, 1.56-3.28, P < .001] for 20-30 smaller nevi and 2.56 [95% CI, 1.50-4.36; P = .003] for 20-30 larger nevi) were significantly associated with the risk of developing a subsequent primary melanoma using multivariate logistic regression analysis. Nonmelanoma skin cancer (OR, 2.57; 95% CI, 1.84-3.58; P < .001) and signs of actinic skin damage, particularly on the back (ORs, 1.91 [95% CI, 1.12-3.25; P = .04] for freckling and 1.92 [95% CI, 1.29-3.08; P = .007] for solar lentigines), additionally increased risk of a subsequent melanoma. All those factors were also associated with an earlier development of the second melanoma. Patients with 3 melanomas developed their second melanoma earlier than patients with only 2 melanomas (mean [SD] age, 55 [15] years for those with 2 primary melanomas; 52 [15] years for those with 3 primary melanomas). Time spent outdoors, solarium use, outdoor occupation, and hair color had no significant associations in these models. According to the results of this study, internal factors (family history and genetic variants), number of nevi, and actinic damage on the back are more relevant for the development of subsequent melanomas than skin phototype or hair color. Patients with many nevi were younger at the time of the diagnosis of their first melanoma. This finding could help to identify persons at increased risk of developing multiple primary melanomas.

Identifiants

pubmed: 30566178
pii: 2718410
doi: 10.1001/jamadermatol.2018.4645
pmc: PMC6439543
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

188-195

Références

J Eur Acad Dermatol Venereol. 2007 Nov;21(10):1333-6
pubmed: 17958838
J Am Acad Dermatol. 2001 Jan;44(1):22-7
pubmed: 11148472
Eur J Cancer Prev. 2018 Nov;27(6):563-569
pubmed: 28692584
In Vivo. 2014 Nov-Dec;28(6):1005-11
pubmed: 25398793
J Eur Acad Dermatol Venereol. 2015 Nov;29(11):2120-7
pubmed: 25864459
J Am Acad Dermatol. 2011 Nov;65(5):1032-47
pubmed: 21868127
Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):2043-54
pubmed: 20647408
Swiss Med Wkly. 2016 Feb 22;146:w14279
pubmed: 26901103
Br J Dermatol. 2017 Apr;176(4):971-978
pubmed: 27596937
Cancer. 1990 Jul 15;66(2):387-95
pubmed: 2369719
Arch Dermatol. 2006 Apr;142(4):433-8
pubmed: 16618861
JAMA Dermatol. 2015 Jun;151(6):607-15
pubmed: 25671687
Cancer. 2002 Apr 15;94(8):2248-55
pubmed: 12001124
Br J Dermatol. 2010 Aug;163(2):238-56
pubmed: 20608932
Cancer Causes Control. 2007 Apr;18(3):295-304
pubmed: 17206532
J Dtsch Dermatol Ges. 2013 Aug;11 Suppl 6:1-116, 1-126
pubmed: 24028775
Pigment Cell Melanoma Res. 2012 Mar;25(2):234-42
pubmed: 22145962
Br J Dermatol. 2012 Dec;167(6):1321-30
pubmed: 22759226
Surgery. 1993 Mar;113(3):330-9
pubmed: 8441968
Br J Dermatol. 2016 Feb;174(2):312-8
pubmed: 26479165
Plast Reconstr Surg. 2004 Jun;113(7):1968-74
pubmed: 15253185
JAMA Dermatol. 2018 Jul 1;154(7):789-795
pubmed: 29898205
Int J Cancer. 2005 Aug 10;116(1):144-9
pubmed: 15761869
Lancet. 2000 Mar 25;355(9209):1072-3
pubmed: 10744096
Int J Dermatol. 2002 Sep;41(9):583-5
pubmed: 12358828
Br J Dermatol. 2014 Sep;171(3):622-30
pubmed: 24665948
J Invest Dermatol. 1994 May;102(5):695-9
pubmed: 8176250
Ann Oncol. 2015 Sep;26 Suppl 5:v126-32
pubmed: 26314774
JAMA Dermatol. 2016 Jul 1;152(7):776-82
pubmed: 27050141
JAMA. 2005 Oct 5;294(13):1647-54
pubmed: 16204664
Cancer Epidemiol. 2011 Dec;35(6):e105-10
pubmed: 21612999
Br J Dermatol. 2016 Jun;174(6):1308-17
pubmed: 26800492
J Am Acad Dermatol. 1998 Sep;39(3):422-7
pubmed: 9738776
Melanoma Res. 2015 Oct;25(5):412-20
pubmed: 26225579

Auteurs

Christoph Müller (C)

Department of Dermatology, Medical University of Vienna, Vienna, Austria.

Judith Wendt (J)

Department of Dermatology, Medical University of Vienna, Vienna, Austria.

Sabine Rauscher (S)

Department of Dermatology, Medical University of Vienna, Vienna, Austria.

Raute Sunder-Plassmann (R)

Clinical Institute for Laboratory Medicine, Medical University of Vienna, Vienna, Austria.

Erika Richtig (E)

Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria.

Ingrid Fae (I)

Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria.

Gottfried Fischer (G)

Department of Blood Group Serology and Transfusion Medicine, Medical University of Vienna, Vienna, Austria.

Ichiro Okamoto (I)

Department of Dermatology, Medical University of Vienna, Vienna, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH